A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT06927349
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Non-Small Cell Lung CancerPancreatic AdenocarcinomaBreast CancerMelanoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 167
- Registration Number
- NCT06596915
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Phase 3
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 510
- Registration Number
- NCT06022861
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Study of BA1202 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT05909241
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 177
- Registration Number
- NCT05650242
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
Phase 1
Completed
- Conditions
- Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer RecurrentMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Shandong Boan Biotechnology Co., Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT05110118
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath